Scott Solomon

List of Publications by Year in Descending Order

42 papers	2,859 citations	20 h-index	46 g-index
46 ext. papers	3,573 ext. citations	11.1 avg, IF	4.14 L-index

#	Paper	IF	Citations
42	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. *New England Journal of Medicine*, **2021**,	59.2	15
41	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. *New England Journal of Medicine*, **2021**,	59.2	14
40	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	1
39	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *JACC: Heart Failure*, **2021**, 9, 374-382	7.9	6
38	Heart failure associated with imported malaria: a nationwide Danish cohort study. *ESC Heart Failure* , **2021**, 8, 3521-3529	3.7	1
37	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. *Journal of Cardiac Failure*, **2021**, 27, 1382-1392	3.3	0
36	Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. *European Heart Journal Cardiovascular Imaging*, **2021**,	4.1	19
35	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. *Hypertension*, **2020**, 76, 808-818	8.5	5
34	Endpoints in Heart Failure Drug Development: History and Future. *JACC: Heart Failure*, **2020**, 8, 429-440	7.9	16
33	Usefulness of Electrocardiographic Left Atrial Abnormality to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure and Left Bundle Branch Block (a Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy). *American Journal of Cardiology*, **2018**, 122, 268-274	3	5
32	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). *American Heart Journal*, **2018**, 199, 130-136	4.9	41
31	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. *American Journal of Hypertension*, **2018**, 31, 407-414	2.3	20
30	Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. *JAMA Cardiology*, **2018**, 3, 357-358	16.2	16
29	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. *Journal of Cardiac Failure*, **2018**, 24, 313-320	3.3	33
28	Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. *Journal of the American Heart Association*, **2017**, 6,	6	19
27	High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2017**, 19, 1303-1309	12.3	20
26	Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. *American Heart Journal*, **2017**, 189, 158-166	4.9	27

25	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. *International Journal of Cardiology*, **2017**, 244, 229-234	3.2	54
24	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. *Annals of Noninvasive Electrocardiology*, **2017**, 22,	1.5	2
23	The tipping point: Value differences and parallel dorsal-ventral frontal circuits gating human approach-avoidance behavior. *NeuroImage*, **2016**, 136, 94-105	7.9	48
22	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. *Circulation: Heart Failure*, **2016**, 9,	7.6	35
21	Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. *Journal of the American College of Cardiology*, **2016**, 67, 303-12	15.1	29
20	Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. *American Heart Journal*, **2015**, 169, 305-14	4.9	18
19	Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. *Circulation: Heart Failure*, **2015**, 8, 448-54	7.6	47
18	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. *European Heart Journal*, **2015**, 36, 440-8	9.5	46
17	Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. *European Journal of Heart Failure*, **2015**, 17, 964-70	12.3	9
16	Response to Letter Regarding Article, Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study *Circulation: Heart Failure*, **2015**, 8, 1010	7.6	
15	Comparison of low versus high (>40 mm Hg) pulse pressure to predict the benefit of cardiac resynchronization therapy for heart failure (from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Trial). *American Journal of Cardiology*, **2014**, 114, 1053-8	3	3
14	Left atrial volume and the benefit of cardiac resynchronization therapy in the MADIT-CRT trial. *Circulation: Heart Failure*, **2014**, 7, 154-60	7.6	26
13	Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *Journal of Clinical Oncology*, **2014**, 32, 2380-5	2.2	327
12	Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). *European Journal of Heart Failure*, **2014**, 16, 1026-38	12.3	97
11	Left ventricular pacing threshold and outcome in MADIT-CRT. *Journal of Cardiovascular Electrophysiology*, **2014**, 25, 1005-1011	2.7	7
10	Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. *European Journal of Heart Failure*, **2014**, 16, 692-9	12.3	42
9	BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 1554-62	12.7	49
8	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *European Journal of Heart Failure*, **2013**, 15, 1082-94	12.3	143

7	Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation*, **2011**, 123, 1061-72	16.7	559
6	Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation*, **2011**, 124, 1527-36	16.7	216
5	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. *Clinical Trials*, **2011**, 8, 165-74	2.2	17
4	Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. *Circulation*, **2011**, 123, 1763-70	16.7	140
3	Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. *Journal of the American College of Cardiology*, **2006**, 47, 1725-7	15.1	17
2	Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. *New England Journal of Medicine*, **2000**, 343, 1688-96	59.2	550
1	Familial dilated cardiomyopathy locus maps to chromosome 2q31. *Circulation*, **1999**, 99, 1022-6	16.7	119